Table 1 Somatic mutations of oncogenes in BCBL-1 and BC-3
From: Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy
Cell line | Gene | Mutation | Genotype | VAFa |
|---|---|---|---|---|
BCBL-1 | BRAF | E501K | Heterozygous | 62% |
BCBL-1 | CHEK2 | S303X | Heterozygous | 61% |
BC-3 | EGFR | R108K | Heterozygous | 65% |
BC-3 | RB1 | Q217X | Homozygous | 100% |